Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Pyrimethamine → Pterin
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | Pyrimethamine | HCID 4993 | — |
| 반응물 | Trimethoprim | HCID 5578 | — |
| 반응물 | Methotrexate | HCID 126941 | — |
| 반응물 | Aminopterin | HCID 169371 | — |
| 반응물 | 2,4-Diamino,5-(3',4'-dichlorophenyl),6-methylpyrimidine trimetrexate | HCID 86753752 | — |
| 반응물 | (4S)-4-[[4-[(2-amino-4-oxo-7,8-dihydro-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate | HCID 136400727 | — |
| 반응물 | HCID 178508907 | HCID 178508907 | — |
| 생성물 | Pterin | HCID 135398660 | — |
반응 단계
When in the above examples, other dihydrofolate reductase inhibitors replace methotrexate, e.g. aminopterin or 10-propargyl-5,8-dideazafolate or 2,4-diamino,5-(3′,4′-dichlorophenyl),6-methylpyrimidine trimetrexate, or pyrimethamine or trimethoprim or pyritrexim 5,10-dideazatetrahydrofolate or 10-ethyl,10-deaza-aminopterin, similar results of pterin salvage pathway blocking are obtained.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US06274581B1 |
| 출처 데이터셋 | uspto-grants-2001_08 |
| ORD ID | ord-4224377c79fb41899e21878a6340b40e |
| 출처 메모 | uspto-grants-2001_08 |